Couple of trades from today, and how I follow the auction to enter trade, as well add to a trade at a higher price. Also trade with the direction of time frame continuity (e.g., D1, W1 up for instance)
Analyzing the options chain and the chart patterns of MRTX Mirati Therapeutics prior to the earnings report this week,
I would consider purchasing the 35usd strike price Puts with
an expiration date of 2023-9-15,
for a premium of approximately $0.57.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking...
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib,...
I spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading.
1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021)
The most important information:
- Initiated potentially registration-enabling trials...
Hey traders, MIRATI THERAPEUTICS is in a great day of its history we can witness a new historical high. It is in a fake bullish surge with a strong buying volume at the start of the session and a hammer bear candle returned. In the TIMEFRAME M1 we can see a panic it goes to its low point which is just below the equilibrium zone. Then start again in its price rise...
MRTX - As per the breakout happened with the volumes also coming in it is expected to go more high from the current levels.
Buy here at current price 209
Maintain stop loss around 194
Target upside 218- 234
Hit the like button to get more signals, Thanks
An intraday high potential, Back Tested Sort Analysis.
We ll try to enter into the correction of the uptrend movement.
DETAILS ON THE CHART
NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances
DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.
Entry level $118 = Target price $137 = Stop loss $115
Bullish price action on the breakout.
OBV indicator very strong as is the RSI
Volume dominated by buyers.
Short interest can still furl the rally at 14%
Company profile
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic,...
Entry level $74 = target price $89 = Stop loss $68.80
Citi analyst Yigal Nochomovitz continues to have favorable expectations for Mirati Therapeutics' (MTRX) initial MRTX849 data in Q4 and believes that a response rate in non-small-cell lung carcinoma in line with Amgen's (AMGN) ~50% should drive the stock "meaningfully higher." In addition, given the small...
AVERAGE ANALYSTS PRICE TARGET $109
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/R RATIO
SHORT INTEREST 12
COMPANY PROFILE
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical...
MRTX was discussed in the trading room last Thursday, and considered a long entry at $4.07 area. It went up 11% today. So how into it should be in good profit.
Who missed it, can look for a break of $4.43 & take a ride. It has good insider buying & it seem it has very strong upside potential.
* Trade Criteria *
Date First Found- July 17, 2017
Pattern/Why-...
MRTX forming a nice fallen angel formation. It is breaking through it moving averages. If it can break above $4.07 it can easily go to $5 area.
* Trade Criteria *
Date First Found- June 21, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $4.07
Exit Target Criteria- $4.93
Stop Loss Criteria- N/A
Please check back for Trade updates....
